Update on emerging urate-lowering therapies

Current Opinion in Rheumatology

Volumn 21, Issue 2, 2009, Pages 143-149

  Chohan, Saima ^a   Becker, Michael A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Allopurinol; Benzbromarone; Febuxostat; Probenecid; Puricase

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; ANTIGOUT AGENT; BENZBROMARONE; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; OXIPURINOL; PEGLOTICASE; PROBENECID; RASBURICASE; RDEA 594; RDEA 806; UNCLASSIFIED DRUG; URICASE MACROGOL 20; Y 700;

AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; GOUT; HUMAN; INJECTION SITE REACTION; LIVER FUNCTION TEST; LIVER TOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ALLOPURINOL; DRUG DISCOVERY; ENZYME INHIBITORS; GOUT; GOUT SUPPRESSANTS; HUMANS; POLYETHYLENE GLYCOLS; THIAZOLES; UNITED STATES; URATE OXIDASE; URIC ACID; URICOSURIC AGENTS; XANTHINE OXIDASE;

EID: 62349137054     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328325bd94     Document Type: Review

References (44)

1. Terkeltaub RA. Gout. N Engl J Med 2003; 349:1647-1655.
2. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann RL. Increasing prevalence of gout and hyperuricemia among older adults in a managed care population. J Rheumatol 2004; 31:1582-1587.
3. Arromdee E, Michet C, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29:2403-2406.
4. Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am 2006; 32:255-273.
5. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3:443-449.
6. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40:37-42.
7. Perez- Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545-549.
8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
9. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52:916-923.
10. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-2461.
11. Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallelgroup trial. Arthritis Rheum Arthritis Care Res 2008; 59:1540-1548. This report documents the urate-lowering superiority of febuxostat (80 and 120 mg) relative to allopurinol (300 mg) and placebo in a 6-month trial. Safety of the agents was compared.
12. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007; 46:1372-1374. The goal range for urate lowering in the proposed guidelines (<5 mg/dl) is more stringent than in the European League Against Rheumatism report (<6 mg/dl).
13. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68:51-56. Documents the urate-lowering superiority of benzbromarone to probenecid in patients failing allopurinol treatment.
14. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/ day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2008. [Epub ahead of print] This is the sole RCT addressing the safety and efficacy of allopurinol at a dose exceeding 300 mg/day.
15. Becker M, Chohan S. Can we make gout management more successful now? Curr Opin Rheumatol 2008; 20:167-172.
16. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol 2006; 18:193-198.
17. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81:925-934.
18. Hak AE, Choi HK. Lifestyle and gout. Curr Opin Rheumatol 2008; 20:179-186.
19. Huang H, Appel JL, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid. Arthritis Rheum 2005; 52:1843-1847.
20. Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32:275-293.
21. Enomoto A, Kimura H, Chairoungdu A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452.
22. Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interests of patients? Drug Saf 2008; 31:643-665.
23. Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using antihyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:572-575.
24. Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10:308-314.
25. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61-65.
26. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacol 1993; 27:337-343.
27. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
28. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007; 20:391-395. This publication discusses the validity and consequences of allopurinol dose reduction in gout patients with renal compromise.
29. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31:2429-2432.
30. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, nonpurine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004; 23:1111-1116.
31. Hoshide S, Nishimura S, Ishii S, et al. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in humans. Drug Metab Rev 2003; 32 (Suppl 2):269.
32. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005; 76:1835-1847.
33. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new selective nonpurine inhibitor of xanthine oxidase, in subjects with renal impairment. Am J Ther 2005; 12:22-34.
34. Becker MA, Schumacher HR Jr, Espinosa L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [abstract]. Arthritis Rheum 2008; 58:4029-4029..
35. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: five-year findings of the FOCUS efficacy and safety study. Rheumatology 2009; 48:188-194.
36. Becker MA, Schumacher HR Jr, MacDonald PA, et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol (in press).
37. Edwards NL Treatment-failure gout: a moving target. Arthritis Rheum 2008; 58:2587-2590. [editorial].
38. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in refractory gout, and induction of antibody against poly(ethylene) glycol(PEG), in a phase 1 trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006; 8:R12.
39. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56:1021-1028.
40. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycolconjugated uricase) in patients with treatment-failure gout. Arthritis Rheum 2008; 58:2882-2891. An open-label, dose-finding study documenting the urate-lowering efficacy and adverse events occurring during a 3-month trial of PGL in patients with TFG.
41. Sundy JS, Baraf HS, Becker MA, et al. Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): results from GOUT 1 and GOUT2 [abstract]. Arthritis Rheum 2008; 58:3400-3401.
42. Baraf HS, Becker MA, Edwards NL, et al. Tophus response to pegloticase (PGL) therapy: pooled results of GOUT1 and GOUT2 PGL phase 3 randomized, doubleblind, placebo-controlled trials [abstract]. Arthritis Rheum 2008; 58:S176.
43. Edwards NL, Baraf HS, Becker MA, et al. Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3 randomized, double blind, placebo (PBO)-controlled trials [abstract]. Arthritis Rheum 2008; 58:S178.
44. Becker MA, Treadwell EL, Baraf HS, et al. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3, randomized: double blind, placebo controlled trials [abstract]. Arthritis Rheum 2008; 58:S880.